SARTORIUS STEDIM BIOTECHSARTORIUS STEDIM BIOTECHSARTORIUS STEDIM BIOTECH

SARTORIUS STEDIM BIOTECH

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪17.03 B‬EUR
1.76EUR
‪309.70 M‬EUR
‪2.78 B‬EUR
‪25.69 M‬
Beta (1Y)
1.21
Employees (FY)
‪10.66 K‬
Change (1Y)
‪−1.27 K‬ −10.66%
Revenue / Employee (1Y)
‪287.32 K‬EUR
Net income / Employee (1Y)
‪32.06 K‬EUR

About SARTORIUS STED BIO


CEO
René Fáber
Headquarters
Aubagne
Founded
1978
ISIN
FR0013154002
FIGI
BBG000R5C950
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The firm offers a broad portfolio of products that focuses on all steps in the manufacture of a biopharmaceutical, as well as in process development as prerequisite procedures. Its technologies cover inter alia, cell line technologies, cell culture media, bioreactors, and a wide range of products for separation, purification, and concentration of biological intermediates and finished products, as well as solutions for storage and transportation. It also offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. The company was founded on September 28, 1978 and is headquartered in Aubagne, France.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 56S1 is 178.10 EUR — it has increased by 1.11% in the past 24 hours. Watch SARTORIUS STEDIM BIOTECH stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange SARTORIUS STEDIM BIOTECH stocks are traded under the ticker 56S1.
56S1 stock has risen by 3.56% compared to the previous week, the month change is a −7.39% fall, over the last year SARTORIUS STEDIM BIOTECH has showed a −12.57% decrease.
We've gathered analysts' opinions on SARTORIUS STEDIM BIOTECH future price: according to them, 56S1 price has a max estimate of 310.00 EUR and a min estimate of 134.00 EUR. Watch 56S1 chart and read a more detailed SARTORIUS STEDIM BIOTECH stock forecast: see what analysts think of SARTORIUS STEDIM BIOTECH and suggest that you do with its stocks.
56S1 reached its all-time high on Sep 13, 2021 with the price of 556.40 EUR, and its all-time low was 140.05 EUR and was reached on Jul 2, 2024. View more price dynamics on 56S1 chart.
See other stocks reaching their highest and lowest prices.
56S1 stock is 1.96% volatile and has beta coefficient of 1.21. Track SARTORIUS STEDIM BIOTECH stock price on the chart and check out the list of the most volatile stocks — is SARTORIUS STEDIM BIOTECH there?
Today SARTORIUS STEDIM BIOTECH has the market capitalization of ‪17.36 B‬, it has decreased by −1.55% over the last week.
Yes, you can track SARTORIUS STEDIM BIOTECH financials in yearly and quarterly reports right on TradingView.
SARTORIUS STEDIM BIOTECH is going to release the next earnings report on Jan 23, 2025. Keep track of upcoming events with our Earnings Calendar.
56S1 earnings for the last quarter are 0.76 EUR per share, whereas the estimation was 0.80 EUR resulting in a −4.68% surprise. The estimated earnings for the next quarter are 0.97 EUR per share. See more details about SARTORIUS STEDIM BIOTECH earnings.
SARTORIUS STEDIM BIOTECH revenue for the last quarter amounts to ‪655.40 M‬ EUR, despite the estimated figure of ‪685.76 M‬ EUR. In the next quarter, revenue is expected to reach ‪710.61 M‬ EUR.
56S1 net income for the last quarter is ‪25.50 M‬ EUR, while the quarter before that showed ‪47.60 M‬ EUR of net income which accounts for −46.43% change. Track more SARTORIUS STEDIM BIOTECH financial stats to get the full picture.
Yes, 56S1 dividends are paid annually. The last dividend per share was 0.69 EUR. As of today, Dividend Yield (TTM)% is 0.39%. Tracking SARTORIUS STEDIM BIOTECH dividends might help you take more informed decisions.
SARTORIUS STEDIM BIOTECH dividend yield was 0.29% in 2023, and payout ratio reached 20.53%. The year before the numbers were 0.48% and 15.15% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 26, 2024, the company has ‪10.66 K‬ employees. See our rating of the largest employees — is SARTORIUS STEDIM BIOTECH on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SARTORIUS STEDIM BIOTECH EBITDA is ‪637.60 M‬ EUR, and current EBITDA margin is 26.02%. See more stats in SARTORIUS STEDIM BIOTECH financial statements.
Like other stocks, 56S1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SARTORIUS STEDIM BIOTECH stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SARTORIUS STEDIM BIOTECH technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SARTORIUS STEDIM BIOTECH stock shows the sell signal. See more of SARTORIUS STEDIM BIOTECH technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.